Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 24

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 24
---
                                                                    |

| • | We seek to establish agreements with potential licensing partners and collaborators and, if we are not                     
 able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans. |

| 13 |

| • | If we enter into agreements with a licensing or collaboration partner for the development and commercialization                           
 of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those 
 collaborations.                                                                                                                           |

| • | The commercial success of any of our product candidates is not guaranteed. |

| • | The pharmaceutical and biotechnology industries are highly competitive. |

| • | Changes in healthcare policies, laws and regulations, including legislative measures aimed at reducing health care costs, may impact 
 our ability to obtain approval for or commercialize any of our future product candidates, if approved.                               |

| • | Coverage and adequate reimbursement may not be available for our                                                
 current or any future product candidates, which could make it difficult for us to sell profitably, if approved. |

| • | Our business may be adversely affected by economic conditions and current economic weakness. |

| • | Our business may be impacted by political events, war, terrorism, business interruptions and other geopolitical 
 events and uncertainties beyond our control.                                                                    |

| • | We may in the future be unable to retain and recruit qualified scientists, key executives, key employees or key consultants, may delay 
 our development efforts or otherwise harm our business.                                                                                |

| • | Public health crises, such as the COVID-19 pandemic, have had, and could in the future have, a negative 
 effect on our business.                                                                                 |

| • | Our success depends in part on our ability to protect rights in our intellectual property, which cannot 
 be assured.                                                                                             |

| • | We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not                                            
 successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize 
 our product candidates and our business could be substantially harmed.                                                                            |

| • | We rely on third parties to manufacture our product candidates, and we expect to continue to rely on third                                      
 parties for the clinical as well as any future commercial supply of our product candidates and other future product candidates. The development 
 of our current and future product candidates, and the commercialization of any approved products, could be stopped, delayed or made less        
 profitable if any such third party fails to provide us